Live GMAT classes with Target Test Prep start Nov 21 and Nov 22. First class free.

See classes
Target Test Prep · GMAT

Choose how you want to prepare

Learn live with an expert or move at your own pace. Every option includes the complete TTP study system.

Newsweek Readers’ Choice Awards 2026 winner: Target Test Prep, #1 Test Prep

Target Test Prep was voted #1 Best Test Prep in the 2026 Newsweek Readers’ Choice™ Awards.

★★★★★5.0563 reviews
GMATLiveTeachStarts Nov 22
Josh Braslow, Target Test Prep GMAT expert
LIVE ONLINE CLASSES

Get Ready for GMAT Test Day Faster with Live Online Classes

with Josh Braslow, 20+ years in test prep

Nov 22 · Josh Braslow
Sun · 9:30 AM to 12:30 PM ET
Included
40 hours of live online classes + 6 months of TTP OnDemand
  • Attend the first class for free
  • Every class is recorded, so you never fall behind
View classes & enroll
Limited seats availableTarget Test Prep
EALiveTeachOnDemandStart anytime
EXECUTIVE ASSESSMENT

Target Test Prep EA OnDemand

Self-paced EA prep. Study on your schedule.

EXECUTIVE ASSESSMENT

with

165+ EA score guarantee
$05-day trial no automatic billing
Schedule
Included
40 hours of live online classes plus six months of access to the complete TTP EA OnDemand course.
  • 165+ EA Score Guarantee
  • 4,100+ Quant, Verbal, and Integrated Reasoning practice questions
  • 400+ hours of in-depth video lessons
  • 3,000+ step-by-step video solutions
View EA class & enroll Start free 5-day trial
Limited cohort · enrollment openTrial includes full course accessTarget Test Prep
GMATOnDemandStart anytime
SELF-PACED MASTERCLASS

Target Test Prep GMAT OnDemand

Complete access from day one. Study on your schedule.

715+ score guarantee
$0to start then $127/mo
  • Personalized study plan and analytics
  • Thousands of lessons and practice questions

Editorial: In a compelling preponderance of clinical trials,

Expert replies
by BTGmoderatorDC » Sat Apr 06, 2019 6:22 pm
Timer
00:00
Your answer
Difficulty–

right wrong

Pick an answer to see how members did

Editorial: In a compelling preponderance of clinical trials, patients who were administered sugar pills on a daily basis reported equally significant improvements in mood as did those patients who were administered FDA-approved antidepressants. Most insurance policies offer policy members only limited coverage for prescriptions of antidepressants, and consequently most such drugs carry an almost prohibitive out-of-pocket cost to consumers. Therefore, medical practitioners (and the media) have a duty to make these clinical findings known to the public, so that those patients who would benefit from such drugs may begin to administer equally effective (and eminently affordable) treatment to themselves, straight out of the kitchen cabinet.

Which of the following, if true, is most damaging to the editorialist’s argument?

A. Each of the clinical trials was conducted over a relatively short period of time, and antidepressants often incite an initial spike in mood which is followed by a return to the original melancholy.

B. The clinical trials based their assessment of mood improvements solely on self-reported data; no objective physiological indicators were measured.

C. The improvements in mood were primarily attributable to the participants’ ongoing belief throughout the trials that they were taking prescription antidepressants.

D. Due to necessary discounting of some participants’ data, the total number of subjects in the sugar pill groups was far greater than the total number of subjects in the FDA-approved antidepressant groups.

E. Most people would be skeptical that taking a substance as common as sugar would bring about a noticeable increase in their mood.

OA C

Source: Veritas Prep
Join the discussion
Source: — Critical Reasoning |